Chicago Atlantic BDC (LIEN) Q4 2025 earnings review
Pristine Credit Holding Up Amid Yield Compression and NII Normalization
Chicago Atlantic BDC capped off FY25 with a flawless 0.0% non-accrual rate and a fully covered $0.34 dividend, supported by a 100% senior-secured portfolio. While Net Investment Income (NII) decelerated sequentially from $0.42 to $0.36, this was largely a normalization following Q3's outsized $1.9M prepayment fee bump. The real story lies in the massive post-quarter capital deployment ($93.9M funded in Q1 2026 thus far) and the Trump administration's executive order to reschedule cannabis, which management believes will serve as a generational catalyst for borrower cash flows.
🐂 Bull Case
Subsequent to year-end, the company funded $93.9M. Even factoring in a $38.3M refinance and $13.6M in payoffs, this represents massive net portfolio growth that will drive significant NII expansion in 2026.
The December 2025 executive order directing the rescheduling of cannabis to Schedule III stands to eliminate the 280E tax burden for borrowers. This dramatically improves operator cash flow profiles, enhancing credit safety and expanding their capacity to take on debt for M&A.
🐻 Bear Case
Gross weighted average yield has compressed from 16.6% in 25Q1 to 15.8% in 25Q4. While still vastly outperforming BDC peers, the premium pricing power is softening slightly.
Despite efforts to diversify (Non-Cannabis is now 25% of the portfolio), the company remains heavily tethered to single-industry regulatory and execution risks.
⚖️ Verdict: 🟢
Bullish. The sequential drop in Q4 NII is a non-issue given it was driven by the absence of one-time Q3 fees. The combination of flawless asset quality, deep downside rate protection, and aggressive post-quarter deployment sets up a highly visible growth trajectory for FY26.
Key Themes
Aggressive Post-Quarter Deployment Accelerating Growth
While Q4 originations were a respectable $31.7M across 7 portfolio companies, activity exploded subsequent to year-end. Management funded $93.9M to seven borrowers, including $35.5M to three new portfolio companies. This represents an enormous step-up in capital deployment that will directly boost the income-generating base in Q1 2026.
Macro Tailwinds: Cannabis Rescheduling & Hemp Loophole Closure
The macro picture improved dramatically in late 2025. President Trump's December executive order to reclassify cannabis to Schedule III targets the crippling 280E tax burden. Simultaneously, Congress banned unregulated hemp-derived THC, forcing consumers back into state-licensed channels. Management views this dual dynamic as a catalyst for borrower cash flow improvement, valuation expansion, and an impending M&A wave.
Deep Downside Protection in a Rate-Cut Cycle
As the Federal Reserve cuts rates, BDC yields typically suffer. Chicago Atlantic has insulated its portfolio: 28.2% of loans are fixed-rate, and 45.2% are floating-rate loans currently sitting at their contractual floors. With over 73% of the portfolio protected from further interest rate declines, the company's yield degradation will be significantly softer than the broader BDC average.
NII Deceleration Highlights Reliance on One-Time Fees
Gross investment income fell from $15.1M in Q3 to $14.2M in Q4, pulling Net Investment Income down from $0.42 to $0.36 per share. This drop exposes a contradiction to the 'perpetual growth' narrative—Q3 was propped up by $1.9M in one-time prepayment premiums. NII of $0.36 is the true fundamental run-rate.
Yield Compression Trajectory
Gross weighted average yield declined across 2025: starting at 16.6% in Q1, dropping to 16.1% in Q2, and settling at 15.8% for both Q3 and Q4. While 15.8% is still an extraordinary premium compared to the 10.8% BDC average, the downward trajectory suggests slightly increased competition or a necessity to offer better pricing to top-tier borrowers.
Other KPIs
Stable and accelerating slightly. Up from $13.27 in 25Q3 and $13.20 a year ago. Maintaining and growing NAV while paying a 10%+ dividend yield points to successful underwriting and zero principal erosion.
Flawless credit performance. The company reported zero loans on non-accrual status at year-end, starkly contrasting with the BDC universe average of 3.3%. This validates management's stringent senior-secured lending criteria.
Decelerating from prior quarters as the company deploys capital. Comprises $2.9M in cash and $75.0M available on the $100M revolving credit facility. By mid-March 2026, liquidity dropped further to $47.5M following the aggressive post-Q4 originations.
Guidance
Stable. The Board declared a regular quarterly dividend of $0.34, marking the sixth consecutive quarter at this rate. It remains fully covered by Q4's $0.36 NII.
Accelerating from the $610 million pipeline reported in Q3. Shows substantial, visible demand for the company's capital across both cannabis and lower middle-market structures.
Key Questions
Post-Quarter Yield Profile
You deployed a massive $93.9M subsequent to year-end. How does the weighted average yield on this new origination cohort compare to the 15.8% portfolio average?
Leverage Philosophy Shift
With the balance on the credit facility rising to fund post-Q4 originations, at what debt-to-equity ratio does the management team intend to cap leverage, given your historical preference for operating essentially unlevered?
Impact of 280E Elimination on Underwriting
If cannabis rescheduling goes through and 280E is eliminated, borrower cash flows will surge. Will you adjust your underwriting standards to allow higher leverage multiples, or will you maintain current parameters and treat the extra cash strictly as a larger margin of safety?